Ding-zhi Huang

Tianjin Key Laboratory Of Cancer Prevention And Therapy
Tianjin, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Author Correction: HDAC6 facilitates LUAD progression by inducing EMT and enhancing macrophage polarization towards the M2 phenotype.

Author Correction: HDAC6 facilitates LUAD progression by inducing EMT and enhancing macrophage polarization towards the M2 phenotype.

Journal: NPJ precision oncology

Published: April 14, 2026

HDAC6 orchestrates metastatic and immunosuppressive programs in small cell lung cancer through S100A2-TGF-β/SMAD and CSF1R signaling.

HDAC6 orchestrates metastatic and immunosuppressive programs in small cell lung cancer through S100A2-TGF-β/SMAD and CSF1R signaling.

Journal: Molecular cancer

Published: September 09, 2025

Extrachromosomal DNA biogenesis is dependent on DNA looping and religation by YY1-Lig3-PARylation complex.

Extrachromosomal DNA biogenesis is dependent on DNA looping and religation by YY1-Lig3-PARylation complex.

Journal: Molecular cell

Published: January 28, 2025

HDAC6 facilitates LUAD progression by inducing EMT and enhancing macrophage polarization towards the M2 phenotype.

HDAC6 facilitates LUAD progression by inducing EMT and enhancing macrophage polarization towards the M2 phenotype.

Journal: NPJ precision oncology

Published: December 31, 2024

The first-in-class bispecific antibody IBI318 (LY3434172) targeting PD-1 and PD-L1 in patients with advanced tumors: a phase Ia/Ib study.

The first-in-class bispecific antibody IBI318 (LY3434172) targeting PD-1 and PD-L1 in patients with advanced tumors: a phase Ia/Ib study.

Journal: Journal of hematology & oncology

Published: October 17, 2024

ACT001 Suppresses the Malignant Progression of Small-Cell Lung Cancer by Inhibiting Lactate Production and Promoting Anti-Tumor Immunity.

ACT001 Suppresses the Malignant Progression of Small-Cell Lung Cancer by Inhibiting Lactate Production and Promoting Anti-Tumor Immunity.

Journal: Thoracic cancer

Published: October 09, 2024

The risks and trends of cardiac-specific mortality associated with chemotherapy or radiotherapy in a large cohort of non-elderly patients with non-small cell lung cancer.

The risks and trends of cardiac-specific mortality associated with chemotherapy or radiotherapy in a large cohort of non-elderly patients with non-small cell lung cancer.

Journal: Translational cancer research

Published: October 03, 2020

Tumor microenvironment interruption: a novel anti-cancer mechanism of Proton-pump inhibitor in gastric cancer by suppressing the release of microRNA-carrying exosomes.

Tumor microenvironment interruption: a novel anti-cancer mechanism of Proton-pump inhibitor in gastric cancer by suppressing the release of microRNA-carrying exosomes.

Journal: American journal of cancer research

Published: May 21, 2017

Change of SPARC expression after chemotherapy in gastric cancer.

Change of SPARC expression after chemotherapy in gastric cancer.

Journal: Cancer biology & medicine

Published: November 22, 2014

Safety analysis of weekly paclitaxel plus S-1 versus paclitaxel plus 5-fluorouracil/calcium folinate as first-line therapy in advanced gastric cancer: a multicenter open random phase II trial.

Safety analysis of weekly paclitaxel plus S-1 versus paclitaxel plus 5-fluorouracil/calcium folinate as first-line therapy in advanced gastric cancer: a multicenter open random phase II trial.

Journal: Journal of chemotherapy (Florence, Italy)

Published: February 26, 2013

A phase II prospective randomized controlled trial of weekly paclitaxel combined with S-1 or fluorouracil for advanced gastric carcinoma

A phase II prospective randomized controlled trial of weekly paclitaxel combined with S-1 or fluorouracil for advanced gastric carcinoma

Journal: Zhonghua zhong liu za zhi [Chinese journal of oncology]

Published: January 08, 2013

Overexpression of cyclin L2 inhibits growth and enhances chemosensitivity in human gastric cancer cells.

Overexpression of cyclin L2 inhibits growth and enhances chemosensitivity in human gastric cancer cells.

Journal: Asian Pacific journal of cancer prevention : APJCP

Published: July 18, 2012

Showing 1-12 of 12

Last Updated: 09/26/2026